7 research outputs found
Bromocriptine treatment associated with recovery from peripartum cardiomyopathy in siblings: two case reports
<p>Abstract</p> <p>Introduction</p> <p>Peripartum cardiomyopathy is a rare form of cardiomyopathy, with heterogeneous presentation occurring in women between one-month antepartum and six months postpartum. It carries a poor prognosis and a high risk of mortality.</p> <p>Case presentation</p> <p>We report the development of peripartum cardiomyopathy in two sisters, 27- and 35-year-old African women, one of whom presented with a large left ventricular thrombus. Subsequently, both patients were treated with bromocriptine, heparin and standard therapy for heart failure (angiotensin converting enzyme inhibitors, beta-blockers and diuretics). During follow-up, the left ventricular thrombus observed in one patient degraded. Neither patient experienced a thrombotic event, and both experienced continuous improvements in cardiac function and New York Heart Association stage.</p> <p>Conclusion</p> <p>The development of peripartum cardiomyopathy in two sisters indicates that there may be a genetic basis for this type of cardiomyopathy, and that women with a positive family history for peripartum cardiomyopathy may have an increased risk of developing the disease. This is also the first report of a patient experiencing degradation of a large left ventricular thrombus under standard therapy for heart failure with bromocriptine. It suggests that the use of bromocriptine in association with adequate anti-coagulation and heart failure therapy may be beneficial and safe.</p
Essential Noninvasive Multimodality Neuromonitoring for the Critically Ill Patient
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2020. Other selected articles can be found online at . Further information about the Annual Update in Intensive Care and Emergency Medicine is available from
The Opportunistic Pathogen Propionibacterium acnes: Insights into Typing, Human Disease, Clonal Diversification and CAMP Factor Evolution
We previously described a Multilocus Sequence Typing (MLST) scheme based on eight genes that facilitates population
genetic and evolutionary analysis of P. acnes. While MLST is a portable method for unambiguous typing of bacteria, it is
expensive and labour intensive. Against this background, we now describe a refined version of this scheme based on two
housekeeping (aroE; guaA) and two putative virulence (tly; camp2) genes (MLST4) that correctly predicted the phylogroup
(IA1, IA2, IB, IC, II, III), clonal complex (CC) and sequence type (ST) (novel or described) status for 91% isolates (n = 372) via
cross-referencing of the four gene allelic profiles to the full eight gene versions available in the MLST database (http://
pubmlst.org/pacnes/). Even in the small number of cases where specific STs were not completely resolved, the MLST4
method still correctly determined phylogroup and CC membership. Examination of nucleotide changes within all the MLST
loci provides evidence that point mutations generate new alleles approximately 1.5 times as frequently as recombination;
although the latter still plays an important role in the bacteriumâs evolution. The secreted/cell-associated âvirulenceâ factors
tly and camp2 show no clear evidence of episodic or pervasive positive selection and have diversified at a rate similar to
housekeeping loci. The co-evolution of these genes with the core genome might also indicate a role in commensal/normal
existence constraining their diversity and preventing their loss from the P. acnes population. The possibility that members of
the expanded CAMP factor protein family, including camp2, may have been lost from other propionibacteria, but not P.
acnes, would further argue for a possible role in niche/host adaption leading to their retention within the genome. These
evolutionary insights may prove important for discussions surrounding camp2 as an immunotherapy target for acne, and
the effect such treatments may have on commensal lineages
Pick Up and Oocyte Management
Pregnancy-related cardiovascular complications are rare clinical conditions that can lead to significant maternal morbidity and mortality. With the implementation of infertility treatment, a new selected population of woman can experience pregnancy. Women with multiple medical problems and women near or beyond menopause are now able to conceive. Despite many unanswered questions, clinicians should be prepared for the challenges and potential cardiovascular complications related to patients who are epidemiologically different than those seen in the past